| review article | Q7318358 |
| scholarly article | Q13442814 |
| P50 | author | Christoph Correll | Q56954221 |
| P2093 | author name string | Lawrence Maayan | |
| P2860 | cites work | Metformin: An Update | Q22241145 |
| A Systematic Review of Mortality in Schizophrenia | Q22253025 | ||
| Leptin responsiveness restored by amylin agonism in diet-induced obesity: evidence from nonclinical and clinical studies | Q24650977 | ||
| From the Cover: Antipsychotic drug-induced weight gain mediated by histamine H1 receptor-linked activation of hypothalamic AMP-kinase | Q24685521 | ||
| Antipsychotic-induced weight gain: a comprehensive research synthesis | Q28146256 | ||
| The role of 5-HT2C receptor polymorphisms in the pharmacogenetics of antipsychotic drug treatment | Q28256285 | ||
| Effectiveness of antipsychotic drugs in patients with chronic schizophrenia | Q28273164 | ||
| Effect of tesofensine on bodyweight loss, body composition, and quality of life in obese patients: a randomised, double-blind, placebo-controlled trial | Q28298603 | ||
| Second-generation versus first-generation antipsychotic drugs for schizophrenia: a meta-analysis | Q28303010 | ||
| Prevalence of baseline serum glucose and lipid testing in users of second-generation antipsychotic drugs: a retrospective, population-based study of Medicaid claims data. | Q31145520 | ||
| Change in metabolic syndrome parameters with antipsychotic treatment in the CATIE Schizophrenia Trial: prospective data from phase 1 | Q31145823 | ||
| Effects of Patient Demographics, Risperidone Dosage, and Clinical Outcome on Body Weight in Acutely Exacerbated Schizophrenia | Q44418398 | ||
| Nizatidine treatment and its relationship with leptin levels in patients with olanzapine-induced weight gain | Q44552626 | ||
| The Effects of an Educational Intervention on Antipsychotic‐Induced Weight Gain | Q44620039 | ||
| A Pilot Study of Risperidone, Olanzapine, and Haloperidol in Psychotic Youth: A Double-Blind, Randomized, 8-Week Trial | Q44635621 | ||
| Effects of antipsychotics on fat deposition and changes in leptin and insulin levels. Magnetic resonance imaging study of previously untreated people with schizophrenia | Q44710936 | ||
| An animal model of antipsychotic-induced weight gain | Q44890737 | ||
| The effect of famotidine addition on olanzapine-induced weight gain in first-episode schizophrenia patients: a double-blind placebo-controlled pilot study | Q44910831 | ||
| Adjunctive fluvoxamine inhibits clozapine-related weight gain and metabolic disturbances | Q45005473 | ||
| Atypical antipsychotics and weight gain in Chinese patients: a comparison of olanzapine and risperidone. | Q45005488 | ||
| Cognitive behavioural therapy for weight gain associated with antipsychotic drugs | Q45009327 | ||
| Plasma leptin and adiposity during antipsychotic treatment of schizophrenia | Q45059332 | ||
| Amantadine for weight gain associated with olanzapine treatment | Q45168614 | ||
| Effect of olanzapine on body composition and energy expenditure in adults with first-episode psychosis | Q45206310 | ||
| Effects of behavioral therapy on weight loss in overweight and obese patients with schizophrenia or schizoaffective disorder. | Q45260562 | ||
| Clinical experience with Topiramate to counteract neuroleptic induced weight gain in 10 individuals with autistic spectrum disorders | Q45287433 | ||
| Glucose dysregulation among veterans living with schizophrenia-related disorders after switching second-generation antipsychotics | Q45331572 | ||
| Extended release metformin for metabolic control assistance during prolonged clozapine administration: a 14 week, double-blind, parallel group, placebo-controlled study. | Q45974367 | ||
| Metabolic risk factors in drug-naive patients with first-episode psychosis. | Q45982515 | ||
| Metabolic risk status and second-generation antipsychotic drug selection: a retrospective study of commercially insured patients. | Q45988528 | ||
| Immediate versus gradual suspension of previous treatments during switch to aripiprazole: results of a randomized, open label study. | Q46012086 | ||
| Association of adiponectin and metabolic syndrome among patients taking atypical antipsychotics for schizophrenia: a cohort study. | Q46028327 | ||
| In search of moderators and mediators of hyperglycemia with atypical antipsychotic treatment | Q46096570 | ||
| Rosiglitazone in the assistance of metabolic control during olanzapine administration in schizophrenia: a pilot double-blind, placebo-controlled, 12-week trial | Q46156977 | ||
| Prevalence and predictors of lipid and glucose monitoring in commercially insured patients treated with second-generation antipsychotic agents | Q46160744 | ||
| Antipsychotic-induced body weight gain: predictors and a systematic categorization of the long-term weight course | Q46182404 | ||
| An exploration of the effect of modafinil on olanzapine associated weight gain in normal human subjects | Q46185982 | ||
| A lifestyle intervention for older schizophrenia patients with diabetes mellitus: a randomized controlled trial. | Q46205584 | ||
| Double-blind comparison of first- and second-generation antipsychotics in early-onset schizophrenia and schizo-affective disorder: findings from the treatment of early-onset schizophrenia spectrum disorders (TEOSS) study | Q46365535 | ||
| A randomized, double-blind, placebo-controlled trial of metformin treatment for weight gain associated with initiation of risperidone in children and adolescents. | Q46438460 | ||
| A double-blind, placebo-controlled trial of sibutramine for olanzapine-associated weight gain. | Q46465959 | ||
| Weight gain associated with olanzapine and risperidone in adolescent patients: a comparative prospective study | Q43910389 | ||
| Phenylpropanolamine appears not to promote weight loss in patients with schizophrenia who have gained weight during clozapine treatment. | Q43986323 | ||
| Weight gain associated with increased food intake and low habitual activity levels in male adolescent schizophrenic inpatients treated with olanzapine | Q44013107 | ||
| Olanzapine-induced weight gain in patients with first-episode schizophrenia: a double-blind, placebo-controlled study of fluoxetine addition | Q44013109 | ||
| Annual medical spending attributable to obesity: payer-and service-specific estimates | Q44104253 | ||
| Peripheral injection of risperidone, an atypical antipsychotic, alters the bodyweight gain of rats | Q44169297 | ||
| Effects of development on olanzapine-associated adverse events | Q44226244 | ||
| Impaired fasting glucose tolerance in first-episode, drug-naive patients with schizophrenia | Q44299748 | ||
| Treatment of weight gain with fluoxetine in olanzapine-treated schizophrenic outpatients | Q44357531 | ||
| Nizatidine for prevention of weight gain with olanzapine: a double-blind placebo-controlled trial | Q44371563 | ||
| Impaired glucose tolerance in first-episode drug-naïve patients with schizophrenia | Q80024902 | ||
| Outcomes of obese, clozapine-treated inpatients with schizophrenia placed on a six-month diet and physical activity program | Q80107999 | ||
| Pharmacogenetics of antipsychotic-induced weight gain | Q80312477 | ||
| Treatment of early-onset schizophrenia spectrum disorders (TEOSS): rationale, design, and methods | Q80713523 | ||
| Treating movement disorders and akathisia as side effects of antipsychotic pharmacotherapy | Q81745600 | ||
| Pharmacotherapy of obesity: emerging drugs and targets | Q83390267 | ||
| Consensus development conference on antipsychotic drugs and obesity and diabetes | Q94355363 | ||
| Switching patients to aripiprazole from other antipsychotic agents: a multicenter randomized study | Q33186211 | ||
| Assessment of strategies for switching patients from olanzapine to risperidone: a randomized, open-label, rater-blinded study | Q33347832 | ||
| Does switching to a new antipsychotic improve outcomes? Data from the CATIE Trial | Q33383396 | ||
| Predictors and correlates for weight changes in patients co-treated with olanzapine and weight mitigating agents; a post-hoc analysis. | Q33423275 | ||
| Weight gain: side effect of atypical neuroleptics? | Q33707031 | ||
| H1-histamine receptor affinity predicts short-term weight gain for typical and atypical antipsychotic drugs. | Q33964839 | ||
| Second-generation (atypical) antipsychotics and metabolic effects: a comprehensive literature review | Q33988376 | ||
| 11-year follow-up of mortality in patients with schizophrenia: a population-based cohort study (FIN11 study). | Q34018491 | ||
| Family-based treatment of severe pediatric obesity: randomized, controlled trial | Q34110691 | ||
| Attenuation of olanzapine-induced weight gain with reboxetine in patients with schizophrenia: a double-blind, placebo-controlled study | Q34174337 | ||
| Physical health monitoring of patients with schizophrenia | Q34337506 | ||
| Inhibitory effects of antipsychotics on carbachol-enhanced insulin secretion from perifused rat islets: role of muscarinic antagonism in antipsychotic-induced diabetes and hyperglycemia | Q34414043 | ||
| Polymorphisms of the 5-HT2C receptor and leptin genes are associated with antipsychotic drug-induced weight gain in Caucasian subjects with a first-episode psychosis | Q34415124 | ||
| Effect of rimonabant, a cannabinoid-1 receptor blocker, on weight and cardiometabolic risk factors in overweight or obese patients: RIO-North America: a randomized controlled trial | Q34494637 | ||
| Risperidone-related weight gain: genetic and nongenetic predictors | Q34516784 | ||
| Nizatidine for the treatment of patients with quetiapine-induced weight gain | Q34544474 | ||
| Abnormalities in glucose regulation during antipsychotic treatment of schizophrenia | Q34583697 | ||
| Lifestyle intervention and metformin for treatment of antipsychotic-induced weight gain: a randomized controlled trial | Q34586878 | ||
| Cardiometabolic risk of second-generation antipsychotic medications during first-time use in children and adolescents | Q34613195 | ||
| The role of histaminergic H1 and H3 receptors in food intake: a mechanism for atypical antipsychotic-induced weight gain? | Q34614012 | ||
| Efficacy and tolerability of olanzapine, quetiapine, and risperidone in the treatment of early psychosis: a randomized, double-blind 52-week comparison | Q34644936 | ||
| A common polymorphism in the cannabinoid receptor 1 (CNR1) gene is associated with antipsychotic-induced weight gain in Schizophrenia | Q34660593 | ||
| Effectiveness of medications used to attenuate antipsychotic-related weight gain and metabolic abnormalities: a systematic review and meta-analysis | Q34661011 | ||
| Prevalence of diabetes, metabolic syndrome and metabolic abnormalities in schizophrenia over the course of the illness: a cross-sectional study | Q34944648 | ||
| A double-blind, placebo-controlled trial of rosiglitazone for clozapine-induced glucose metabolism impairment in patients with schizophrenia | Q34974099 | ||
| Metabolic side effects of antipsychotic drug treatment--pharmacological mechanisms | Q35014069 | ||
| Congruencies in increased mortality rates, years of potential life lost, and causes of death among public mental health clients in eight states | Q35024510 | ||
| Pharmacogenetics of antipsychotic-induced side effects | Q35237129 | ||
| A comparison of risperidone-induced weight gain across the age span | Q35825542 | ||
| Twenty-five year mortality of a community cohort with schizophrenia | Q36028183 | ||
| Weight gain in newly diagnosed first-episode psychosis patients and healthy comparisons: one-year analysis | Q36178681 | ||
| Endocrine and metabolic adverse effects of psychotropic medications in children and adolescents | Q36532942 | ||
| Weight gain and metabolic effects of mood stabilizers and antipsychotics in pediatric bipolar disorder: a systematic review and pooled analysis of short-term trials | Q36827082 | ||
| Sustained weight loss following 12-month pramlintide treatment as an adjunct to lifestyle intervention in obesity | Q36842060 | ||
| A case series: evaluation of the metabolic safety of aripiprazole | Q36853249 | ||
| Early evaluation of patient risk for substantial weight gain during olanzapine treatment for schizophrenia, schizophreniform, or schizoaffective disorder | Q36934711 | ||
| Antipsychotic use in children and adolescents: minimizing adverse effects to maximize outcomes | Q37050190 | ||
| Changes in non-high-density lipoprotein cholesterol levels and triglyceride/high-density lipoprotein cholesterol ratios among patients randomized to aripiprazole versus olanzapine | Q37161980 | ||
| Ethnic heterogeneity in glucoregulatory function during treatment with atypical antipsychotics in patients with schizophrenia | Q37162718 | ||
| Compelling or irrelevant? Using number needed to treat can help decide | Q37163467 | ||
| Pharmacological management of atypical antipsychotic-induced weight gain. | Q37165503 | ||
| Strategies for dosing and switching antipsychotics for optimal clinical management. | Q37165544 | ||
| Metabolic screening after the American Diabetes Association's consensus statement on antipsychotic drugs and diabetes | Q37189197 | ||
| The future of endocannabinoid-oriented clinical research after CB1 antagonists. | Q37226111 | ||
| Non-pharmacological management of antipsychotic-induced weight gain: systematic review and meta-analysis of randomised controlled trials. | Q37231472 | ||
| Metabolic profile of antipsychotic-naive individuals with non-affective psychosis | Q37245422 | ||
| Weight gain and metabolic abnormalities during extended risperidone treatment in children and adolescents | Q37273061 | ||
| The metabolic syndrome and schizophrenia | Q37365657 | ||
| A UK audit of screening for the metabolic side effects of antipsychotics in community patients | Q37427104 | ||
| Efficacy of behavioural interventions in managing atypical antipsychotic weight gain | Q37457102 | ||
| Contributing factors to weight gain during long-term treatment with second-generation antipsychotics. A systematic appraisal and clinical implications | Q37491329 | ||
| Are weight gain and metabolic side effects of atypical antipsychotics dose dependent? A literature review | Q37572026 | ||
| Aripiprazole monotherapy for maintenance therapy in bipolar I disorder: a 100-week, double-blind study versus placebo | Q38394215 | ||
| Cardiovascular morbidity and mortality associated with the metabolic syndrome | Q39513407 | ||
| Worldwide ethnic distribution of the G protein beta3 subunit 825T allele and its association with obesity in Caucasian, Chinese, and Black African individuals. | Q39517168 | ||
| Glucose metabolism in patients with schizophrenia treated with atypical antipsychotic agents: a frequently sampled intravenous glucose tolerance test and minimal model analysis | Q39704211 | ||
| A cognitive/behavioral group intervention for weight loss in patients treated with atypical antipsychotics | Q39747219 | ||
| Mifepristone reduces weight gain and improves metabolic abnormalities associated with risperidone treatment in normal men. | Q39888640 | ||
| Orlistat in clozapine- or olanzapine-treated patients with overweight or obesity: a 16-week randomized, double-blind, placebo-controlled trial | Q42164052 | ||
| Weight development in patients treated with risperidone: a 5-year naturalistic study | Q42169005 | ||
| Interventions to reduce weight gain in schizophrenia | Q42419226 | ||
| Weight gain during treatment of bipolar I patients with olanzapine. | Q42644649 | ||
| Effects of switching from olanzapine to risperidone on the prevalence of the metabolic syndrome in overweight or obese patients with schizophrenia or schizoaffective disorder: analysis of a multicenter, rater-blinded, open-label study | Q42681472 | ||
| Metabolic screening in children receiving antipsychotic drug treatment | Q43109191 | ||
| Topiramate for prevention of olanzapine associated weight gain and metabolic dysfunction in schizophrenia: a double-blind, placebo-controlled trial | Q43140698 | ||
| Risperidone associated weight, leptin, and anthropometric changes in children and adolescents with psychotic disorders in early treatment | Q43145177 | ||
| Do antipsychotic medications reduce or increase mortality in schizophrenia? A critical appraisal of the FIN-11 study | Q43198845 | ||
| Metabolic testing rates in 3 state Medicaid programs after FDA warnings and ADA/APA recommendations for second-generation antipsychotic drugs | Q43202669 | ||
| ADRA1A gene is associated with BMI in chronic schizophrenia patients exposed to antipsychotics | Q43240883 | ||
| Improved body weight and metabolic outcomes in overweight or obese psychiatric patients switched to amisulpride from other atypical antipsychotics | Q43243100 | ||
| Understanding the relationship between baseline BMI and subsequent weight change in antipsychotic trials: effect modification or regression to the mean? | Q43246326 | ||
| Mifepristone treatment of olanzapine-induced weight gain in healthy men. | Q43248853 | ||
| A naturalistic study of predictors and risks of atypical antipsychotic use in an attention-deficit/hyperactivity disorder clinic | Q43251748 | ||
| Low ratio of fat to carbohydrate oxidation as predictor of weight gain: study of 24-h RQ. | Q43431480 | ||
| Factors influencing acute weight change in patients with schizophrenia treated with olanzapine, haloperidol, or risperidone | Q43622360 | ||
| Influence of topiramate on olanzapine-related adiposity in women: a random, double-blind, placebo-controlled study | Q46474918 | ||
| Association between early and rapid weight gain and change in weight over one year of olanzapine therapy in patients with schizophrenia and related disorders | Q46474943 | ||
| A multicenter, randomized, double-blind study of the effects of aripiprazole in overweight subjects with schizophrenia or schizoaffective disorder switched from olanzapine | Q46498360 | ||
| Nutritional intervention to prevent weight gain in patients commenced on olanzapine: a randomized controlled trial | Q46534674 | ||
| Topiramate add-on treatment in schizophrenia: a randomised, double-blind, placebo-controlled clinical trial | Q46565043 | ||
| Topiramate as an adjuvant treatment with atypical antipsychotics in schizophrenic patients experiencing weight gain | Q46630469 | ||
| Effectiveness of antipsychotic drugs in first-episode schizophrenia and schizophreniform disorder: an open randomised clinical trial | Q46675364 | ||
| Metformin plus sibutramine for olanzapine-associated weight gain and metabolic dysfunction in schizophrenia: a 12-week double-blind, placebo-controlled pilot study | Q46675714 | ||
| Double-blind, placebo-controlled investigation of amantadine for weight loss in subjects who gained weight with olanzapine | Q46681225 | ||
| Prevalence of the metabolic syndrome in patients with schizophrenia: baseline results from the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) schizophrenia trial and comparison with national estimates from NHANES III. | Q46683011 | ||
| Metabolic syndrome in first episode schizophrenia - a randomized double-blind controlled, short-term prospective study. | Q46762146 | ||
| Metformin addition attenuates olanzapine-induced weight gain in drug-naive first-episode schizophrenia patients: a double-blind, placebo-controlled study | Q46775479 | ||
| A psychoeducational program for weight loss in patients who have experienced weight gain during antipsychotic treatment with olanzapine | Q46802759 | ||
| The metabolic syndrome is associated with reduced central serotonergic responsivity in healthy community volunteers | Q46816757 | ||
| A 12-week, randomized, open-label, parallel-group trial of topiramate in limiting weight gain during olanzapine treatment in patients with schizophrenia | Q46834427 | ||
| Management of antipsychotic-induced weight gain: prospective naturalistic study of the effectiveness of a supervised exercise programme | Q46902584 | ||
| Association of antipsychotic induced weight gain and body mass index with GNB3 gene: a meta-analysis | Q47216014 | ||
| Effect of coadministration of clozapine and fluvoxamine versus clozapine monotherapy on blood cell counts, plasma levels of cytokines and body weight | Q47239559 | ||
| HTR2C haplotypes and antipsychotics-induced weight gain: X-linked multimarker analysis | Q47274265 | ||
| Long-term changes in weight and plasma lipids during maintenance treatment with ziprasidone | Q47279555 | ||
| Appropriate intervention strategies for weight gain induced by olanzapine: a randomized controlled study. | Q47286539 | ||
| Metformin as an adjunctive treatment to control body weight and metabolic dysfunction during olanzapine administration: a multicentric, double-blind, placebo-controlled trial | Q47289112 | ||
| Attenuating effect of reboxetine on appetite and weight gain in olanzapine-treated schizophrenia patients: a double-blind placebo-controlled study | Q47300367 | ||
| A double-blind, placebo-controlled trial of sibutramine for clozapine-associated weight gain. | Q47304572 | ||
| Weight gain management in patients with schizophrenia during treatment with olanzapine in association with nizatidine | Q47304705 | ||
| A randomized, double-blind, placebo-controlled trial of metformin treatment of weight gain associated with initiation of atypical antipsychotic therapy in children and adolescents | Q47310987 | ||
| Attenuation of antipsychotic-induced weight gain with early behavioral intervention in drug-naive first-episode psychosis patients: A randomized controlled trial | Q47322107 | ||
| Energy expenditure and physical activity in clozapine use: implications for weight management | Q47325485 | ||
| Weight management program for treatment-emergent weight gain in olanzapine-treated patients with schizophrenia or schizoaffective disorder: A 12-week randomized controlled clinical trial. | Q47339231 | ||
| Metformin for prevention of weight gain and insulin resistance with olanzapine: a double-blind placebo-controlled trial | Q47341566 | ||
| Weight gain induced by clozapine | Q47342297 | ||
| Weight change in treatment with olanzapine and a psychoeducational approach | Q47342812 | ||
| Prevention of antipsychotic-induced weight gain with early behavioural intervention in first-episode psychosis: 2-year results of a randomized controlled trial | Q47587063 | ||
| Impact of antipsychotic treatments on the motivation to eat: preliminary results in 153 schizophrenic patients | Q48268486 | ||
| Insulin resistance and adiponectin levels in drug-free patients with schizophrenia: A preliminary report. | Q51496104 | ||
| A placebo-controlled, random-assignment, parallel-group pilot study of adjunctive topiramate for patients with schizoaffective disorder, bipolar type. | Q51899626 | ||
| Obesity as a risk factor for antipsychotic noncompliance. | Q51944586 | ||
| The impact of weight gain on quality of life among persons with schizophrenia. | Q51949599 | ||
| A clinical trial of the efficacy and acceptability of D-fenfluramine in the treatment of neuroleptic-induced obesity. | Q52069574 | ||
| The association between HTR2C polymorphisms and obesity in psychiatric patients using antipsychotics: a cross-sectional study | Q57317087 | ||
| Treatment of Pediatric Overweight: An Examination of Feasibility and Effectiveness in an Applied Clinical Setting | Q58641695 | ||
| Attenuation of Antipsychotic-Induced Weight Gain With Early Behavioral Intervention in Drug-Naive First-Episode Psychosis Patients | Q60603227 | ||
| Ten-year follow-up of behavioral, family-based treatment for obese children | Q68590166 | ||
| Family history of type 2 diabetes in schizophrenic patients | Q69367752 | ||
| FAILURE OF DEXTROAMPHETAMINE SULFATE TO INFLUENCE EATING AND SLEEPING PATTERNS IN OBESE SCHIZOPHRENIC PATIENTS: CLINICAL AND PHARMACOLOGICAL SIGNIFICANCE | Q78425549 | ||
| Acute effects of atypical antipsychotics on whole-body insulin resistance in rats: implications for adverse metabolic effects | Q79226756 | ||
| Improvement in antipsychotic-related metabolic disturbances in patients with schizophrenia switched to ziprasidone | Q79385758 | ||
| Effectiveness of switching antipsychotic medications | Q79411250 | ||
| P433 | issue | 7 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | weight gain | Q3403879 |
| P304 | page(s) | 1175-200 | |
| P577 | publication date | 2010-07-01 | |
| P1433 | published in | Expert Review of Neurotherapeutics: a key contribution to decision making in the treatment of neurologic and neuropsychiatric disorders | Q15760319 |
| P1476 | title | Management of antipsychotic-related weight gain | |
| P478 | volume | 10 |
| Q90353605 | A commentary on the efficacy of olanzapine for the treatment of schizophrenia: the past, present, and future |
| Q90468190 | A narrative review of the success of intramuscular gluteal injections and its impact in psychiatry |
| Q64991805 | Acetazolamide for Antipsychotic-Associated Weight Gain in Schizophrenia. |
| Q64060745 | Altered gene expression in antipsychotic-induced weight gain |
| Q34648940 | Antipsychotic drugs and obesity |
| Q37043479 | Antipsychotic drugs opposite to metabolic risk: neurotransmitters, neurohormonal and pharmacogenetic mechanisms underlying with weight gain and metabolic syndrome |
| Q28266158 | Association between common variants near the melanocortin 4 receptor gene and severe antipsychotic drug-induced weight gain |
| Q61907409 | Atypical Antipsychotic Exposure May Not Differentiate Metabolic Phenotypes of Patients with Schizophrenia |
| Q48336234 | Decreased 5-HT2cR and GHSR1a interaction in antipsychotic drug-induced obesity |
| Q38709352 | Diabetes and Schizophrenia |
| Q38283956 | Do antipsychotics increase diabetes risk in children and adolescents? |
| Q37684797 | Does a GLP-1 receptor agonist change glucose tolerance in patients treated with antipsychotic medications? Design of a randomised, double-blinded, placebo-controlled clinical trial |
| Q36075717 | Effectiveness of a cognitive behavioral weight management intervention in obese patients with psychotic disorders compared to patients with nonpsychotic disorders or no psychiatric disorders: results from a 12-month, real-world study |
| Q50072523 | Enhancing metabolic monitoring for children and adolescents using second-generation antipsychotics |
| Q36060797 | Gender and race disparities in weight gain among offenders prescribed antidepressant and antipsychotic medications |
| Q37354917 | Improving metabolic parameters of antipsychotic child treatment (IMPACT) study: rationale, design, and methods |
| Q60949949 | Less Medication Use in Inpatients With Severe Mental Illness Receiving a Multidisciplinary Lifestyle Enhancing Treatment. The MULTI Study III |
| Q34464293 | Managing cardiovascular disease risk in patients treated with antipsychotics: a multidisciplinary approach |
| Q37947095 | Metabolic and cardiovascular adverse effects associated with antipsychotic drugs |
| Q34292768 | Metabolic consequences of second-generation antipsychotics in youth: appropriate monitoring and clinical management |
| Q92776030 | Metformin Attenuates Liver Fat Content: Finding from Schizophrenia Patients with Olanzapine-induced Weight Gain |
| Q36966228 | Molecular and behavioral pharmacology of two novel orally-active 5HT2 modulators: potential utility as antipsychotic medications |
| Q37954390 | Obesity and psychotropics. |
| Q41634413 | Once-monthly paliperidone palmitate in early stage schizophrenia - a retrospective, non-interventional 1-year study of patients with newly diagnosed schizophrenia |
| Q64332771 | Patient, Treatment, and Health Care Utilization Variables Associated with Adherence to Metabolic Monitoring Practices in Children and Adolescents Taking Second-Generation Antipsychotics |
| Q92022051 | Phenotypic factors associated with amisulpride-induced weight gain in first-episode psychosis patients (from the OPTiMiSE cohort) |
| Q37479158 | Physical activity level and medial temporal health in youth at ultra high-risk for psychosis |
| Q35016170 | Physical illness in patients with severe mental disorders. II. Barriers to care, monitoring and treatment guidelines, plus recommendations at the system and individual level. |
| Q57164581 | Predictors and Moderators of Antipsychotic-Related Weight Gain in the Treatment of Early-Onset Schizophrenia Spectrum Disorders Study |
| Q33835596 | Preliminary and ongoing French multicenter prospective naturalistic study of adverse events of antipsychotic treatment in naive children and adolescents. |
| Q89964094 | Progress in Genetic Polymorphisms Related to Lipid Disturbances Induced by Atypical Antipsychotic Drugs |
| Q35145284 | Risperidone induced weight gain leading to benign intracranial hypertension |
| Q64068123 | Role of Leptin in Mood Disorder and Neurodegenerative Disease |
| Q38656912 | Running for your life: A review of physical activity and cardiovascular disease risk reduction in individuals with schizophrenia |
| Q38123236 | Safety of olanzapine use in adolescents |
| Q33878816 | Safety, tolerability, and risks associated with first- and second-generation antipsychotics: a state-of-the-art clinical review |
| Q61943520 | Second-generation antipsychotics and metabolism alterations: a systematic review of the role of the gut microbiome |
| Q64114784 | Sex differences in gene expression related to antipsychotic induced weight gain |
| Q47228167 | Superwellness Program: a cognitive-behavioral therapy-based group intervention to reduce weight gain in patients treated with antipsychotic drugs |
| Q37637480 | The Obesity-Impulsivity Axis: Potential Metabolic Interventions in Chronic Psychiatric Patients. |
| Q33849136 | The concomitant use of second-generation antipsychotics and long-term antiretroviral therapy may be associated with increased cardiovascular risk |
| Q64071490 | Understanding the Mechanism of Action and Clinical Implications of Anti-Obesity Drugs Recently Approved in Korea |
| Q38504254 | Weight gain and obesity in schizophrenia: epidemiology, pathobiology, and management |
| Q38838191 | Weight gain with add-on second-generation antipsychotics in bipolar disorder: a naturalistic study |
Search more.